Peritoneal Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：218頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Peritoneal Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Peritoneal Cancer - Pipeline Review, H1 2014’, provides an overview of the Peritoneal Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Peritoneal Cancer - Pipeline Review, H1 2014’, provides an overview of the Peritoneal Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Peritoneal Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Peritoneal Cancer - Overview 11
Pipeline Products for Peritoneal Cancer - Comparative Analysis 12
Peritoneal Cancer - Therapeutics under Development by Companies 13
Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Peritoneal Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Peritoneal Cancer - Products under Development by Companies 21
Peritoneal Cancer - Products under Investigation by Universities/Institutes 23
Peritoneal Cancer - Companies Involved in Therapeutics Development 24
Boehringer Ingelheim GmbH 24
AstraZeneca PLC 25
GlaxoSmithKline plc 26
Bioniche Life Sciences, Inc. 27
Daiichi Sankyo Company, Limited 28
Oxford BioMedica plc 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
ImmunoGen, Inc. 32
Bayer AG 33
Incyte Corporation 34
Oncolytics Biotech Inc. 35
Pharmacyclics, Inc. 36
Synta Pharmaceuticals Corp. 37
Oasmia Pharmaceutical AB 38
MabVax Therapeutics, Inc. 39
Spectrum Pharmaceuticals, Inc. 40
Acceleron Pharma, Inc. 41
TRION Pharma GmbH 42
CerRx, Inc. 43
OncoMed Pharmaceuticals, Inc. 44
TetraLogic Pharmaceuticals 45
Innate Therapeutics Limited 46
CritiTech, Inc. 47
Immunotope, Inc. 48
Immunovaccine, Inc. 49
Pharma Mar, S.A. 50
VentiRx Pharmaceuticals, Inc. 51
Genelux Corporation 52
Clovis Oncology, Inc. 53
California Stem Cell, Inc. 54
EGEN, Inc. 55
Advanced Accelerator Applications 56
Peritoneal Cancer - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Target 58
Assessment by Mechanism of Action 62
Assessment by Route of Administration 66
Assessment by Molecule Type 69
Drug Profiles 72
pazopanib hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
paclitaxel - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MEK-162 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
trabectedin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
sorafenib tosylate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
alisertib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
selumetinib sulfate - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
dalantercept - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
elesclomol - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
TroVax - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
pelareorep - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
nintedanib - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
catumaxomab - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
VTX-2337 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
exatecan mesylate - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
EGEN-001 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
NSC-748933 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
INCB-24360 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
birinapant - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
rucaparib - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
metformin - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Cancer Stem Cell Therapy - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
fenretinide - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
DPX-Survivac - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
ganetespib - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
pralatrexate - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
demcizumab - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
GL-ONC-1 - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
abexinostat hydrochloride - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
8H9-MAb - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
IMT-1012 - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
paclitaxel - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
MV-NIS Vaccine - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
IMGN-853 - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
OC-DC Vaccine - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
MIS-416 - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 154
Theranean - Drug Profile 156
Product Description 156
Mechanism of Action 156
R&D Progress 156
Peritoneal Cancer - Recent Pipeline Updates 157
Peritoneal Cancer - Dormant Projects 212
Peritoneal Cancer - Discontinued Products 213
Peritoneal Cancer - Product Development Milestones 214
Featured News & Press Releases 214
Nov 01, 2012: Genelux Announces Early Results Of Phase I/II Clinical Trial Of Virotherapeutic GL-ONC1 In Advanced Peritoneal Cavity Cancers 214
Sep 20, 2012: Roche's Avastin Obtains Positive Opinion From CHMP To Treat Various Cancers 215
May 31, 2012: Genelux Announces Treatment Of First Patient In Phase I/II Clinical Trial Of GL-ONC1 In Advanced Peritoneal Cavity Cancers 216
Appendix 217
Methodology 217
Coverage 217
Secondary Research 217
Primary Research 217
Expert Panel Validation 217
Contact Us 218
Disclaimer 218
List of Tables
Number of Products under Development for Peritoneal Cancer, H1 2014 11
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Development by Companies, H1 2014 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 24
Peritoneal Cancer - Pipeline by AstraZeneca PLC, H1 2014 25
Peritoneal Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 26
Peritoneal Cancer - Pipeline by Bioniche Life Sciences, Inc., H1 2014 27
Peritoneal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 28
Peritoneal Cancer - Pipeline by Oxford BioMedica plc, H1 2014 29
Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 30
Peritoneal Cancer - Pipeline by Novartis AG, H1 2014 31
Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H1 2014 32
Peritoneal Cancer - Pipeline by Bayer AG, H1 2014 33
Peritoneal Cancer - Pipeline by Incyte Corporation, H1 2014 34
Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014 35
Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H1 2014 36
Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 37
Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2014 38
Peritoneal Cancer - Pipeline by MabVax Therapeutics, Inc., H1 2014 39
Peritoneal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 40
Peritoneal Cancer - Pipeline by Acceleron Pharma, Inc., H1 2014 41
Peritoneal Cancer - Pipeline by TRION Pharma GmbH, H1 2014 42
Peritoneal Cancer - Pipeline by CerRx, Inc., H1 2014 43
Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 44
Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2014 45
Peritoneal Cancer - Pipeline by Innate Therapeutics Limited, H1 2014 46
Peritoneal Cancer - Pipeline by CritiTech, Inc., H1 2014 47
Peritoneal Cancer - Pipeline by Immunotope, Inc., H1 2014 48
Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H1 2014 49
Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H1 2014 50
Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2014 51
Peritoneal Cancer - Pipeline by Genelux Corporation, H1 2014 52
Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H1 2014 53
Peritoneal Cancer - Pipeline by California Stem Cell, Inc., H1 2014 54
Peritoneal Cancer - Pipeline by EGEN, Inc., H1 2014 55
Peritoneal Cancer - Pipeline by Advanced Accelerator Applications, H1 2014 56
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Stage and Target, H1 2014 60
Number of Products by Stage and Mechanism of Action, H1 2014 64
Number of Products by Stage and Route of Administration, H1 2014 68
Number of Products by Stage and Molecule Type, H1 2014 71
Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H1 2014 157
Peritoneal Cancer - Dormant Projects, H1 2014 212
Peritoneal Cancer - Discontinued Products, H1 2014 213
List of Figures
Number of Products under Development for Peritoneal Cancer, H1 2014 11
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Top 10 Target, H1 2014 58
Number of Products by Stage and Top 10 Target, H1 2014 59
Number of Products by Top 10 Mechanism of Action, H1 2014 62
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 63
Number of Products by Top 10 Route of Administration, H1 2014 66
Number of Products by Stage and Top 10 Route of Administration, H1 2014 67
Number of Products by Top 10 Molecule Type, H1 2014 69
Number of Products by Stage and Top 10 Molecule Type, H1 2014 70
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Peritoneal Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Peritoneal Cancer - Overview 11
Pipeline Products for Peritoneal Cancer - Comparative Analysis 12
Peritoneal Cancer - Therapeutics under Development by Companies 13
Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Peritoneal Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Peritoneal Cancer - Products under Development by Companies 21
Peritoneal Cancer - Products under Investigation by Universities/Institutes 23
Peritoneal Cancer - Companies Involved in Therapeutics Development 24
Boehringer Ingelheim GmbH 24
AstraZeneca PLC 25
GlaxoSmithKline plc 26
Bioniche Life Sciences, Inc. 27
Daiichi Sankyo Company, Limited 28
Oxford BioMedica plc 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
ImmunoGen, Inc. 32
Bayer AG 33
Incyte Corporation 34
Oncolytics Biotech Inc. 35
Pharmacyclics, Inc. 36
Synta Pharmaceuticals Corp. 37
Oasmia Pharmaceutical AB 38
MabVax Therapeutics, Inc. 39
Spectrum Pharmaceuticals, Inc. 40
Acceleron Pharma, Inc. 41
TRION Pharma GmbH 42
CerRx, Inc. 43
OncoMed Pharmaceuticals, Inc. 44
TetraLogic Pharmaceuticals 45
Innate Therapeutics Limited 46
CritiTech, Inc. 47
Immunotope, Inc. 48
Immunovaccine, Inc. 49
Pharma Mar, S.A. 50
VentiRx Pharmaceuticals, Inc. 51
Genelux Corporation 52
Clovis Oncology, Inc. 53
California Stem Cell, Inc. 54
EGEN, Inc. 55
Advanced Accelerator Applications 56
Peritoneal Cancer - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Target 58
Assessment by Mechanism of Action 62
Assessment by Route of Administration 66
Assessment by Molecule Type 69
Drug Profiles 72
pazopanib hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
paclitaxel - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MEK-162 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
trabectedin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
sorafenib tosylate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
alisertib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
selumetinib sulfate - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
dalantercept - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
elesclomol - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
TroVax - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
pelareorep - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
nintedanib - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
catumaxomab - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
VTX-2337 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
exatecan mesylate - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
EGEN-001 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
NSC-748933 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
INCB-24360 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
birinapant - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
rucaparib - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
metformin - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Cancer Stem Cell Therapy - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
fenretinide - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
DPX-Survivac - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
ganetespib - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
pralatrexate - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
demcizumab - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
GL-ONC-1 - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
abexinostat hydrochloride - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
8H9-MAb - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
IMT-1012 - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
paclitaxel - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
MV-NIS Vaccine - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
IMGN-853 - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
OC-DC Vaccine - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
MIS-416 - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 154
Theranean - Drug Profile 156
Product Description 156
Mechanism of Action 156
R&D Progress 156
Peritoneal Cancer - Recent Pipeline Updates 157
Peritoneal Cancer - Dormant Projects 212
Peritoneal Cancer - Discontinued Products 213
Peritoneal Cancer - Product Development Milestones 214
Featured News & Press Releases 214
Nov 01, 2012: Genelux Announces Early Results Of Phase I/II Clinical Trial Of Virotherapeutic GL-ONC1 In Advanced Peritoneal Cavity Cancers 214
Sep 20, 2012: Roche's Avastin Obtains Positive Opinion From CHMP To Treat Various Cancers 215
May 31, 2012: Genelux Announces Treatment Of First Patient In Phase I/II Clinical Trial Of GL-ONC1 In Advanced Peritoneal Cavity Cancers 216
Appendix 217
Methodology 217
Coverage 217
Secondary Research 217
Primary Research 217
Expert Panel Validation 217
Contact Us 218
Disclaimer 218
List of Tables
Number of Products under Development for Peritoneal Cancer, H1 2014 11
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Development by Companies, H1 2014 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 24
Peritoneal Cancer - Pipeline by AstraZeneca PLC, H1 2014 25
Peritoneal Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 26
Peritoneal Cancer - Pipeline by Bioniche Life Sciences, Inc., H1 2014 27
Peritoneal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 28
Peritoneal Cancer - Pipeline by Oxford BioMedica plc, H1 2014 29
Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 30
Peritoneal Cancer - Pipeline by Novartis AG, H1 2014 31
Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H1 2014 32
Peritoneal Cancer - Pipeline by Bayer AG, H1 2014 33
Peritoneal Cancer - Pipeline by Incyte Corporation, H1 2014 34
Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014 35
Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H1 2014 36
Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 37
Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2014 38
Peritoneal Cancer - Pipeline by MabVax Therapeutics, Inc., H1 2014 39
Peritoneal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 40
Peritoneal Cancer - Pipeline by Acceleron Pharma, Inc., H1 2014 41
Peritoneal Cancer - Pipeline by TRION Pharma GmbH, H1 2014 42
Peritoneal Cancer - Pipeline by CerRx, Inc., H1 2014 43
Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 44
Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2014 45
Peritoneal Cancer - Pipeline by Innate Therapeutics Limited, H1 2014 46
Peritoneal Cancer - Pipeline by CritiTech, Inc., H1 2014 47
Peritoneal Cancer - Pipeline by Immunotope, Inc., H1 2014 48
Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H1 2014 49
Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H1 2014 50
Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2014 51
Peritoneal Cancer - Pipeline by Genelux Corporation, H1 2014 52
Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H1 2014 53
Peritoneal Cancer - Pipeline by California Stem Cell, Inc., H1 2014 54
Peritoneal Cancer - Pipeline by EGEN, Inc., H1 2014 55
Peritoneal Cancer - Pipeline by Advanced Accelerator Applications, H1 2014 56
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Stage and Target, H1 2014 60
Number of Products by Stage and Mechanism of Action, H1 2014 64
Number of Products by Stage and Route of Administration, H1 2014 68
Number of Products by Stage and Molecule Type, H1 2014 71
Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H1 2014 157
Peritoneal Cancer - Dormant Projects, H1 2014 212
Peritoneal Cancer - Discontinued Products, H1 2014 213
List of Figures
Number of Products under Development for Peritoneal Cancer, H1 2014 11
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Top 10 Target, H1 2014 58
Number of Products by Stage and Top 10 Target, H1 2014 59
Number of Products by Top 10 Mechanism of Action, H1 2014 62
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 63
Number of Products by Top 10 Route of Administration, H1 2014 66
Number of Products by Stage and Top 10 Route of Administration, H1 2014 67
Number of Products by Top 10 Molecule Type, H1 2014 69
Number of Products by Stage and Top 10 Molecule Type, H1 2014 70
